Ушбу ишга иқтибос қилган ишлар

2 та иш

Иш: Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

1. Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan

   James M. Trauer, Jay Achar, Nargiza Parpieva +7

   МақолаTuberculosis Research and EpidemiologyBMC Medicine20163 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.195695

2. Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan

   Johanna Kuhlin, Chris Smith, Atadjan Khaemraev +8

   МақолаTuberculosis Research and EpidemiologyThe International Journal of Tuberculosis and Lung Disease20181 иқтибос

   ABIABI:AkademIndex/openalex/2018.article.000181